The swiftly burgeoning study of the earlier twenty years on agonist-antagonist analgesics and opioid receptors makes this exhaustive evaluate of opioid anal­ gesics relatively proper and well timed. After an introductory bankruptcy the extra 12 chapters commence logically with morphine and congeners (4- epoxymorphinans) and finish with opioid receptors.

Extra resources for Controlling Biochemical Weapons: Adapting Multilateral Arms Control for the 21st Century (Global Issues)

Example text

6 Mill. 69 In addition, the CWC stipulates intermediate destruction deadlines at certain intervals after entry into force. It soon became evident that Russia would not achieve the first of these intermediate deadlines in April 2000. 70 However, this goal also was not realized and Russia had again to apply for extending not only the intermediate, but also the final destruction deadline. 71 What is more, the deadline for the complete destruction of the Russian CW arsenal in this second request for extending the deadlines slipped from 2007 to 2012.

The following section introduces the BW prohibition regime and its development through the activities of subsequent BWC Review Conferences, and the Australia Group. The attempts to strengthen the regime through the negotiation of a legally binding protocol to the BWC are then dealt with. The final section analyses the development of the BW prohibition regime since the 5th Review Conference and asks to what extent the regime in its current form is able to contain the dangers emanating from the new scientific and technological developments in the life sciences.

This was largely due to the huge commercial success of two drugs, Epogen and Neupogen produced by one company, Amgen. Since then, the number of new drugs based on biotechnological production methods has increased dramatically, as has the number of companies in the biotechnology sector. While only a few start-ups populated the commercial biotechnology scene in the late 1970s and early 1980s, by the end of the century most major pharmaceutical companies had moved into the area and the worldwide number of biotech companies had grown to several thousand: Less than 30 years ago the industry began with a handful of US start-ups using genetic engineering to manufacture commercial quantities of well-characterized human protein drugs.